C-Path Receives Largest Data Transfer to Date from UK’s National Neonatal Research Database The EPR data transfer is the first from the United Kingdom and includes data from nearly 200 hospitals TUCSON, Ariz., June
FSHD Society and Critical Path Institute Collaborate to Collect Clinical Trial Data TUCSON, Ariz., May 23, 2022 — The FSHD Society, a research-focused patient advocacy nonprofit dedicated to bringing treatments
C-Path to Lead Novel Pre-Consortium Framework for Optimizing the Rare and Orphan Medical Product Lifecycle TUCSON, Ariz., April 28, 2022 — Critical Path Institute (C-Path), in collaboration with one of the industry’s prominent r
Longtime Pharmaceutical Executive to Lead C-Path’s Sickle Cell Disease Consortium TUCSON, Ariz., April 14, 2022 – Critical Path Institute (C-Path) has named Sergey Rakhilin, Ph.D., as Executive Director of its
C-Path Receives Qualification Opinion from EMA on Type 1 Diabetes Biomarker Initiative TUCSON, Ariz., April 5, 2022 — Critical Path Institute’s (C-Path) Type 1 Diabetes Consortium (T1DC) today announced that the E
C-Path European Nonprofit Established in Amsterdam C-Path in Europe works seamlessly with its U.S. counterpart to advance the development of novel regulatory-endorsed methodologies
C-Path and Tufts Medical Center Collaborate on EHR Data Transfer The endeavor represents a major milestone for C-Path TUCSON, Ariz., March 10, 2022 — Critical Path Institute (C-Path) and
C-Path and the European Joint Programme on Rare Diseases to Expand Global Impact and Partnership PARIS, France and TUCSON, Ariz., U.S., February 1, 2022 — Critical Path Institute (C-Path), an independent global nonprofit orga
C-Path Appoints Health Outcomes Expert as Executive Director of the Rare Disease COA Consortium Dr. Lindsey Murray will lead C-Path’s New Rare Disease COA Consortium TUCSON, Ariz., January 13, 2022 — Critical Path Institut
C-Path Launches Rare Disease Clinical Outcome Assessment Consortium The Rare Disease COA Consortium aims to advance patient-focused assessment of clinical benefit in treatment trials for rare diseas